Pfizer and BioNTech expect to seek emergency use authorization for their COVID-19 booster vaccine in all adults 18 years and older; the Biden administration urges appeals court to not block employer vaccine mandate; nearly 8 in 10 Americans believe or are unsure of false COVID-19 information.
As reported by The Washington Post, Pfizer/BioNTech are expected to seek emergency use authorization for their COVID-19 booster vaccine in all adults 18 years and older. The request, which could be filed as soon as this week, will likely be approved by the FDA and comes amid concerns from some health experts that infections and deaths from the declining Delta surge might be plateauing at a high level. Currently, the Pfizer booster shots are available for individuals 65 years and older or those aged 18 to 64 who are at high risk of severe COVID-19 or work in areas that increase risk.
The Biden administration issued a 28-page filing yesterday to the United States Court of Appeals for the Fifth Circuit arguing that the federal government had all the necessary power to require large employers to mandate COVID-19 vaccination or weekly testing and mask wearing in their workforce. Following the court’s temporary halting of the mandate last week, The New York Times reports the Department of Justice contended that the rule was necessary to protect workers from the pandemic and had legal standing. If passed, the rule would force companies with at least 100 employees to require unvaccinated employees to wear masks starting December 5 and adhere to weekly testing at work starting January 4.
A poll published yesterday by Kaiser Family Foundation indicated that 78% of US adults believe or are unsure of at least 1 of 8 false statements regarding COVID-19. As reported by The Hill, trends in misinformation included 38% who believe the government is exaggerating COVID-19 deaths, 17% who believe pregnant women should not get the vaccine, and 18% who believe vaccine-related deaths are being hidden by the government. Notably, unvaccinated individuals were found to be much more likely to believe or be unsure of 4 or more of the false statements compared with vaccinated people (64% vs 19%).
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More